A bundle for those who want to enhance the effectiveness of GLP-1 receptors or Cagrilintide by combining them in one protocol.

How is this protocol more effective than monotherapy?

•  Better appetite suppression than either supplement alone

•  Maintains satiety longer after meals

•  Better blood sugar control

•  Reduced insulin resistance

•  More effective weight loss

Cagrilintide and GLP-1 receptors have similar effects but completely different mechanisms of action, which is why all effects are enhanced during combination therapy.

The combination of Cagrilintide and Semaglutide has already been tested in humans, and the combination drug is currently undergoing clinical trials (*Frias et al., 2023,Tymothy Garvey et al., 2025*) and is showing excellent results.

Some users have already tried not only the combination with Cagrilintide and Semaglutide, but also with other GLP-1 medications—Tirzepatide and Rutatrutide, which studies show are more effective than Semaglutide.

Therefore, we would like to present three bundles, each with a GLP-1 receptor, available in our shop.

⚠️ IMPORTANT INSTRUCTIONS AND RECOMMENDATIONS

1. Dosage:

• The dosages described in this description are approximate. Do not increase the dosage if you feel unwell.
• Increase the dosage only if the current dosage is not effective enough.
• Once the desired appetite suppression and weight loss effect is achieved, stay at current dose.

2. Injections:

• DO NOT MIX IN THE SAME SYRINGE.
• Do not inject into the same site to avoid irritation.
• Injections are given on the same day once a week.

3. Precautions:

• Do not use if you have a history of pancreatitis, severe GI disorders, pregnancy, or medullary thyroid carcinoma (for GLP-1 agents).
• It is advisable to track fasting glucose, HbA1c, electrolytes, liver function, and pancreatic enzymes regularly during treatment.

Cagrilintide + Semaglutide

A clinically proven combination that significantly enhances weight reduction beyond monotherapy. Semaglutide improves glucose control and reduces hunger, while Cagrilintide prolongs satiety and helps prevent rebound appetite.

Protocol EXAMPLE

(Do not increase dosage if side effects occur or more frequently than every 4 weeks)

Cagrilintide + Tirzepatide

A next-generation dual-incretin protocol combining Cagrilintide’s amylin action with Tirzepatide’s GIP + GLP-1 receptor activation. This pairing provides exceptional metabolic synergy, amplifying fat oxidation and energy regulation.

Protocol EXAMPLE

(Do not increase dosage if side effects occur or more frequently than every 4 weeks)

Cagrilintide + Retatrutide

The most potent combination currently available, Retatrutide activates GLP-1, GIP, and glucagon receptors, while Cagrilintide targets the amylin pathway. Glucagon receptor activation adds a thermogenic effect — increasing energy expenditure and fat oxidation — which, together with enhanced appetite suppression, leads to exceptional body-fat reduction and improved metabolic outcomes.

Protocol EXAMPLE

(Do not increase dosage if side effects occur or more frequently than every 4 weeks)

Select the GLP-1 medication you want to combine with Cagrilintide